1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Cancer Immunotherapy Market Outlook 2020

Global Cancer Immunotherapy Market Outlook 2020

  • June 2015
  • 2600 pages
  • ID: 4397216
  • Format: PDF
  • By Kuick Research


Table of Contents

Immune system is an intricate network of various tissues, organs and cell that prevents the attack by infectious agents. It prevents the growth and development of pathogens in body that may cause disease development. Wide array of potential disease causing microorganism like bacteria, fungus and virus are identified and eliminated in the body. Immune system also has ability to identify self from foreign cells due to which transplant rejection is observed. It has capability to generate memory that helps in providing long-term memory. Dead and abnormal cell are removed from the body that may hinder the normal functioning of cellular processes. It could also be trained to identify and eliminate particular cells from the body by giving suitable cues. Investigators have utilized this property of immune system to treat diseases by modulating immune responses. Investigators have extended this modality for preventing cancer progression and proliferation by stimulating patients’ immune system.

Cancer immunotherapies have evolved significantly and numerous products have been introduced in the market. Many cancer immunotherapies are being tested in clinical trials for identification of their pharmacological and commercialization potential. Novel cancer immunotherapies are at different stages of clinical trials which would be introduced in coming years in global market. They could be broadly divided in two classes: specific and non-specific cancer immunotherapy. Basis of this classification is their ability to identify specific antigen related to particular malignancy. Modality used for developing them may be different but all of them will involve the activation of immune system for elimination of cancer. In some cases, overlapping boundaries may be found which is quite possible because single cancer immunotherapy may have multiple effects.

Cancer immunotherapeutics segment seems to be quite dynamic as it has received highly developed products which are absent in other cancer therapeutic category. This category has large number of products belonging to different categories resulting in myriad choices for patients to choose suitable products according to their necessities. They have been able to create dominance in cancer market segment of pharmaceutical industry which is expected to be continued for several years. Some of the products belonging to cancer immunotherapy were introduced few decades ago, while others have received marketing approval in past few years.

Versatility of these cancer immunotherapies allow them to be administrated for different cancer indications due to which their market share is increasing. Different cancer immunotherapy products have different pharmacological profiles due to which some products shows more acceptance rates as compared to other cancer immunotherapies. However, they have superior pharmacological capabilities as compared to their conventional counterparts.

Cancer immunotherapies harbor targeted therapeutics for the treatment of some malignancies. They have been made to target few antigens putatively linked to the cancerous cells. As a result, they have been introduced for limited malignancies due which large unmet medical necessities are observed in this segment. This fact was recognized by pharmaceutical companies and they started to lay emphasis on identification of new biomarkers. Biomarker identification followed by their development is a complex process and requires lots of time. This issue was solved by using knowledge from bioinformatics and allied fields which has been able to save time, investments and precious resources. However, pharmacological and commercialization potential of cancer therapeutics based on novel biomarkers would be known by clinical data.

New modalities, biomarkers and underlying principles are expected to be introduced in global market in coming years. These changes are expected to be propelled by increased fundings and technological advancement in the field of cancer immunotherapeutics. This scenario shows that they are going to play an important role in the treatment of various malignancies. All these facts show that cancer immunotherapies are going to have an optimistic future.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H2 2019SummaryWilms Tumor Protein (WT33 or WT1) pipeline Target constitutes close to 16 molecules. Out of which approximately 8 molecules are developed ...

Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, H2, 2019

Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Metastatic Transitional (Urothelial) Tract Cancer Global Clinical Trials Review, ...

Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2019

Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2019SummaryTumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on